A5034287641- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Gastrointestinal Tumor Research and Treatment
- Cancer therapeutics and mechanisms
- Metastasis and carcinoma case studies
- Lung Cancer Treatments and Mutations
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Pharmacogenetics and Drug Metabolism
- Genetic factors in colorectal cancer
- Drug Transport and Resistance Mechanisms
- Hepatocellular Carcinoma Treatment and Prognosis
- Esophageal Cancer Research and Treatment
- Colorectal and Anal Carcinomas
- Lymphoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Surgical Treatments
- Cancer Genomics and Diagnostics
- Neonatal Health and Biochemistry
- Neutropenia and Cancer Infections
- Sarcoma Diagnosis and Treatment
- Growth Hormone and Insulin-like Growth Factors
- Cancer, Hypoxia, and Metabolism
Oita University
2015-2024
National Cancer Center Hospital East
2002-2015
Oita University Hospital
2013
National Cancer Center
1999-2010
Tokyo National Hospital
1995-2009
Shizuoka Cancer Center
2007-2009
Saitama Cancer Center
2007-2009
Shikoku Cancer Center
1999-2009
The Cancer Institute Hospital
2009
Tokyo Medical and Dental University
2009
NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of doxorubicin (DXR) and one successful polymer micelle systems to exhibit an efficient accumulation in solid tumours mice. The purpose this study was define maximum-tolerated dose (MTD) dose-limiting toxicities (DLTs) evaluate its pharmacokinetic profile man. given intravenously patients with every 3 weeks using infusion pump at rate 10 mg DXR equivalent min−1. starting 6 m−2, escalated according accelerated...
To compare fluorouracil (FU) alone with FU plus cisplatin (FP) and uracil tegafur mitomycin (UFTM) for patients advanced gastric cancer in a prospective, randomized, controlled trial.A total of 280 were randomly allocated analyzed survival, response, toxicity. The survival curves compared between groups by log-rank test on an intent-to-treat basis.At the interim analysis, UFTM arm showed significantly inferior higher incidences hematologic toxic effects than did control alone, registration...
BACKGROUND Although regional lymph node metastasis from intramucosal early gastric carcinoma (EGC) is rare, it very important to clarify the characteristics of patients having nodal metastases in order determine appropriate therapy. METHODS The authors investigated 1196 with solitary EGC who underwent resection at National Cancer Center Hospital Tokyo, special reference metastases. Eight clinicopathologic factors (age, sex, tumor: size, location, macroscopic type, histologic ulceration...
Objectives SN-38, an active metabolite of irinotecan, is detoxified by glucuronidation with UGT1A isoforms, 1A1, 1A7, 1A9, and 1A10. The pharmacogenetic information on haplotypes covering all these isoforms important for the individualized therapy irinotecan. Associations between pharmacokinetics/pharmacodynamics irinotecan were investigated to identify markers. Methods area under concentration curve ratio (SN-38 glucuronide/SN-38) or toxicities analyzed in 177 Japanese cancer patients...
This phase I study was designed to examine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), recommended (RD) for II, and pharmacokinetics of NK105, a new polymeric micelle carrier system paclitaxel (PTX). NK105 administered as 1-h intravenous infusion every 3 weeks, without antiallergic premedication. The starting 10 mg m(-2), escalated according accelerated titration method. Nineteen patients were recruited. tumour types treated included pancreatic (n=11), bile duct (n=5),...
PURPOSE: A phase II study of a combination chemotherapy regimen cisplatin (CDDP) and irinotecan (CPT-11) was conducted to assess its efficacy feasibility in patients with metastatic gastric cancer. PATIENTS AND METHODS: Eligibility criteria included the following: (1) histologically proven cancer measurable lesions, (2) performance status 2 or less, (3) age 75 years younger, (4) one no prior regimens, (5) adequate bone marrow, liver, renal, cardiac functions, (6) written informed consent....
A dose-escalation study of cisplatin (CDDP) combined with S-1, a new oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended (RD), dose-limiting toxicities (DLTs), and objective response rate (RR) in advanced gastric cancer (AGC). S-1 given orally at 40 mg m−2 b.i.d. for 21 consecutive days following 2-week rest. CDDP planned be intravenously on day 8, 60, 70, or 80 depending DLT. Treatment repeated every 5...
LBA4513 Backgrounds: We conducted a 3-arm phase III study to investigate superiority of CP and non-inferiority S-1 5-FU for advanced gastric cancer in the primary endpoint overall survival (OS) secondary endpoints response rate (RR), time treatment failure (TTF), non-hospitalized (NHS) toxicities. Methods: Treatments with (800mg/m 2 /d, ci, d1–5, q4w), (irinotecan, 70mg/m , div, d1&15 cisplatin, 80mg/m d1, q4w) (40mg/m b.i.d., d1- 28, q6w) were continued until disease progression or...
In order to identify single nucleotide polymorphisms (SNPs) and haplotype frequencies of CYP3A4 in a Japanese population, the distal enhancer proximal promoter regions, all exons, surrounding introns were sequenced from genomic DNA 416 subjects. We found 24 SNPs, including 17 novel ones: two enhancer, four promoter, one 5′-untranslated region (UTR), seven introns, three 3′-UTR. The most common SNP was c.1026+12G>A (IVS10+12G>A), with 0.249 frequency. Four non-synonymous c.554C>G (p.T185S,...
PURPOSE A dose-escalation study of irinotecan hydrochloride (CPT-11) combined with fixed-dose cisplatin was conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and objective response rate in patients advanced gastric cancer. PATIENTS AND METHODS Twenty-four or without prior chemotherapy were enrolled. All assessable for toxicities response. On day 1, CPT-11 administered as a 90-minute intravenous (I.V.) infusion, which followed 2 hours later by 120-minute I.V....
We performed comprehensive haplotyping of ABCB1/MDR1 gene blocks using 49 genetic polymorphisms, including seven novel ones, obtained from 145 Japanese subjects. The was divided into four (Blocks -1, 1, 2, and 3) based on linkage disequilibrium analysis polymorphisms. Using an expectation-maximization program, 8, 3 haplotype groups (3, 12, 32, 18 haplotypes) were identified in Blocks 3, respectively. Within Block *1, *2, *4, *6, *8 reported by Kim colleagues (Clin Pharmacol Ther 2001;...
Epidermal growth factor receptor (EGFR) is highly expressed in some gastric cancers and implicated cancer cell proliferation. The objective of this study was to assess the situ biologic activity EGFR tyrosine kinase inhibitor gefitinib tumor samples a phase II study.Patients with previously treated stage IV adenocarcinoma stomach or gastroesophageal junction were randomly assigned receive (250 500 mg/d). Tumor biopsies, obtained at screening on day 28 treatment, assessed for biomarker...
Expression levels of insulin-like growth factor type 1 receptor (IGF-IR), epidermal (EGFR), and HER2 expressions have been linked to clinical outcomes in several solid tumors. However, the significance these biomarkers gastric cancer (GC) remains unclear. This study was designed delineate implications three GC.The group comprised 87 patients who underwent gastrectomy at National Cancer Center Hospital subsequently received chemotherapy for recurrent or residual Using immunohistochemical...
ObjectiveOwing to the risks of serious and sustained toxicity, anticancer drugs such as cisplatin irinotecan cannot be readily administered patients with gastric cancer severe peritoneal metastasis. Therefore, a standard chemotherapy regimen has yet established for these types patients. This randomized study investigated utility sequential methotrexate 5-fluorouracil therapy vs. continuous infusion
Abstract BACKGROUND The goal of the current study was to evaluate objective response rate and toxicity associated with oral fluoropyrimidine S‐1 (a combination tegafur, 5‐chloro‐2,4‐dihydroxypyridine, potassium oxonate) in patients previously untreated metastatic colorectal carcinoma. METHODS Thirty‐eight were enrolled study. administered orally at a dose 40 mg/m 2 twice daily for 28 days, followed by 14‐day rest period. Treatment repeated every 6 weeks unless disease progression observed....
Using laser-captured microdissection and a real-time RT–PCR assay, we quantitatively evaluated mRNA levels of the following biomarkers in paraffin-embedded gastric cancer (GC) specimens obtained by surgical resection or biopsy: excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase (DPD), methylenetetrahydrofolate reductase (MTHFR), epidermal growth factor receptor (EGFR), five other related to anticancer drug sensitivity. The study group comprised 140 patients...
Background: Although adjuvant radiotherapy was proved to be effective for local control of rectal cancer even after standardized mesorectal excision, the role chemotherapy such surgery remains clarified. We aimed assess efficacy a combination uracil and tegafur pathological stage III treated by excision with selective lateral pelvic lymphadenectomy.
Endoscopic biopsy prior to chemotherapy provides an opportunity for studying biomarkers predict the overall survival in gastric cancer patients. This prospective study was performed identify prognostic patients with unresected cancer. Fifty‐nine cases of chemotherapy‐naive metastatic were enrolled this study. A microarray analysis using 40 samples candidate genes whose expressions might be correlated survival. After adjusting clinical covariates based on a multivariate analysis, identified...